Skip to main content
Top
Published in: Breast Cancer Research 2/2005

01-06-2005 | Poster Presentation

HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells

Authors: S Yoon, M-Y Lee, B-W Park, K-S Kim

Published in: Breast Cancer Research | Special Issue 2/2005

Login to get access

Excerpt

Overexpression of the HER2 oncogene is observed in approximately 30% of human breast carcinoma specimens. HER2-overexpressing breast cancer cells, such as SK-BR-3 and BT-474 cells, express fatty acid synthase (FAS) at a higher level than MCF-7 cells or MDA-MB-231 cells, where HER2 is expressed at a moderate or low level. Adenovirus-mediated HER2 expression in MDA-MB-231 cells increased acetyl-CoA carboxylase alpha (ACCα) and FAS protein levels without significant increases of their mRNA. HER2-mediated increases of ACCα and FAS proteins were inhibited by the PI3K inhibitor, LY294002, and the mTOR inhibitor, rapamycin. But sterol regulatory element-binding protein 1 (SREBP1) and ATP citrate lyase (ACL) mRNA and protein levels were not changed by HER2 overexpression, LY294002 or rapamycin. In conclusion, our results suggest that HER2-overexpressing cells lead to increased ACCα and FAS proteins at a translational level via the activation of the mTOR signaling pathway and not through SREBP-1c-mediated transcriptional activation. …
Metadata
Title
HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells
Authors
S Yoon
M-Y Lee
B-W Park
K-S Kim
Publication date
01-06-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 2/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1132

Other articles of this Special Issue 2/2005

Breast Cancer Research 2/2005 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine